The short answer is no — most medical devices imported or manufactured in China do not require a full clinical trial for registration. In fact, the National Medical Products Administration (NMPA 国家药品监督管理局) exempts over 80% of medical device registrations from clinical trials through its exemption catalog and alternative clinical evaluation routes. However, the specific requirements depend heavily on the device classification, risk level, and whether the device has a proven track record in China or comparable markets. Understanding these pathways is essential for foreign executives planning market entry.
How NMPA Classifies Medical Devices and Links to Clinical Trial Requirements
China’s medical device regulatory system under the NMPA (国家药品监督管理局) divides devices into three risk-based categories. Class I (第一类 dì yī lèi) devices are low-risk and generally require no clinical data at all. Class II (第二类 dì èr lèi) devices are medium-risk and can often use a clinical evaluation report (CER 临床评价报告) rather than a trial. Class III (第三类 dì sān lèi) devices are high-risk and may require a full clinical trial (临床试验 línchuáng shìyàn), depending on their novelty and prior approval history.
The classification determines the registration pathway. For Class I devices, registration is a straightforward filing process — no clinical evidence is needed. For Class II devices, the NMPA accepts CERs that analyze existing clinical data, literature, or data from predicate devices. Only Class III devices and certain high-risk Class II devices face the possibility of a mandatory clinical trial.
What surprises many foreign executives is that even most Class III devices can avoid clinical trials if they have been legally marketed in China for a certain period or are listed in the NMPA’s exemption catalog (免于临床试验目录 miǎn yú línchuáng shìyàn mùlù). The catalog currently covers more than 5,000 device types, including many Class III devices such as coronary stents and pacemakers that have established safety records.
Three Pathways to Registration: Exemption, CER, and Clinical Trial
When registering a medical device in China, you have three potential pathways depending on your device classification and history. Understanding which pathway applies to your device can save months of regulatory time and millions of yuan in costs.
Pathway 1: Clinical Trial Exemption. If your device is listed in the NMPA’s “Exempted Clinical Trial Catalog” (免于临床试验目录), you do not need to conduct a clinical trial at all. This catalog covers over 5,000 device types, spanning both Class II and Class III devices. Instead of a trial, you submit a declaration of conformity and relevant technical documentation. This is the fastest and cheapest route, typically requiring only 6 to 12 months for registration.
Pathway 2: Clinical Evaluation Report (CER). If your device is not in the exemption catalog but has a predicate device already approved in China, you can compile a CER. This report analyzes clinical data from the predicate device, published literature, and your own device’s technical specifications. The NMPA accepts CERs for many Class II and some Class III devices. A well-prepared CER typically takes 8 to 18 months to compile and review, at a cost of approximately 20% to 30% of a full clinical trial.
Pathway 3: Full Clinical Trial. If your device is high-risk, novel, or has no predicate in China, a full clinical trial is mandatory. This applies to approximately 15–20% of Class III devices — particularly innovative medical devices (创新医疗器械 chuàngxīn yīliáo qìxiè) that use new materials, mechanisms of action, or treat conditions with no existing approved treatment in China. A full trial requires an NMPA-qualified hospital, ethical approval, and can take 18 to 36 months from trial design to final registration.
When Clinical Trials Are Mandatory: High-Risk and Innovative Devices
Clinical trials are not the default in China — they are the exception. However, for certain device categories, the NMPA explicitly requires clinical data from a China-based trial conducted at NMPA-certified hospitals. Understanding exactly when this applies is critical for budgeting and timeline planning.
The NMPA mandates clinical trials for devices that meet any of these criteria. First, the device belongs to a high-risk category not listed in the exemption catalog, such as many Class III implantable devices that use novel biomaterials. Second, the device is classified as an innovative medical device under the NMPA’s special approval pathway — these devices have no predicate in China and must demonstrate safety and efficacy through local clinical data. Third, the device has been recalled or involved in adverse events in other markets, triggering heightened NMPA scrutiny.
A critical nuance: even exempt devices may require clinical data if the manufacturer changes the device’s intended use, adds new claims, or modifies the design in ways that affect safety. The NMPA’s 2022 guidance on clinical evaluation emphasizes that the “substantial equivalence” standard is stricter than in the US or EU — China requires direct comparison data, not just similarity arguments.
For foreign manufacturers, the most unexpected requirement is often the need for local clinical data from a Chinese population. Even if your device has extensive clinical data from Europe or the US, the NMPA may still require a small-scale China-based trial to confirm safety and efficacy in Chinese patients. This is particularly common for Class III devices that interact with the cardiovascular, central nervous, or endocrine systems.
Real Cost and Timeline Comparison: Trial vs. No-Trial Routes
The cost difference between clinical trial pathways and non-trial pathways is substantial. A full clinical trial in China can cost between ¥2,000,000 and ¥10,000,000 depending on the device complexity, number of patients, and number of trial sites. In contrast, the clinical evaluation report (CER) pathway typically costs ¥200,000 to ¥500,000, while the exemption pathway costs only ¥50,000 to ¥100,000 for documentation and filing.
Timelines also vary dramatically. The exemption pathway can achieve registration in 6 to 12 months from submission. The CER pathway takes 8 to 18 months. A full clinical trial takes 18 to 36 months from trial design to final registration. These timeline differences directly impact market entry strategy and revenue projections. Below is a detailed comparison based on 2024 NMPA data and industry benchmarks from medical device consulting firms operating in China.
| Pathway | Applicable Devices | Average Cost (CNY) | Average Timeline | Clinical Data Required |
|---|---|---|---|---|
| Exemption Catalog | Class II & III devices listed in catalog | ¥50,000–¥100,000 | 6–12 months | Declaration of conformity only |
| Clinical Evaluation Report (CER) | Devices with predicate in China | ¥200,000
 ContactTell us what you need to set up, verify, source, or coordinate in China. We turn the context into a practical next step. © 2021 tagDiv. All Rights Reserved. Made with Newspaper Theme. |